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Abstract
Introduction: Consensus criteria for pediatric severe sepsis have standardized enrollment for research studies.
However, the extent to which critically ill children identified by consensus criteria reflect physician diagnosis of
severe sepsis, which underlies external validity for pediatric sepsis research, is not known. We sought to determine
the agreement between physician diagnosis and consensus criteria to identify pediatric patients with severe sepsis
across a network of international pediatric intensive care units (PICUs).
Methods: We conducted a point prevalence study involving 128 PICUs in 26 countries across 6 continents. Over
the course of 5 study days, 6925 PICU patients <18 years of age were screened, and 706 with severe sepsis defined
either by physician diagnosis or on the basis of 2005 International Pediatric Sepsis Consensus Conference consensus
criteria were enrolled. The primary endpoint was agreement of pediatric severe sepsis between physician diagnosis
and consensus criteria as measured using Cohen’s κ. Secondary endpoints included characteristics and clinical
outcomes for patients identified using physician diagnosis versus consensus criteria.
Results: Of the 706 patients, 301 (42.6 %) met both definitions. The inter-rater agreement (κ ± SE) between physician
diagnosis and consensus criteria was 0.57 ± 0.02. Of the 438 patients with a physician’s diagnosis of severe sepsis, only
69 % (301 of 438) would have been eligible to participate in a clinical trial of pediatric severe sepsis that enrolled
patients based on consensus criteria. Patients with physician-diagnosed severe sepsis who did not meet consensus
criteria were younger and had lower severity of illness and lower PICU mortality than those meeting consensus criteria
or both definitions. After controlling for age, severity of illness, number of comorbid conditions, and treatment in
developed versus resource-limited regions, patients identified with severe sepsis by physician diagnosis alone or by
consensus criteria alone did not have PICU mortality significantly different from that of patients identified by both
physician diagnosis and consensus criteria.
Conclusions: Physician diagnosis of pediatric severe sepsis achieved only moderate agreement with consensus criteria,
with physicians diagnosing severe sepsis more broadly. Consequently, the results of a research study based on
consensus criteria may have limited generalizability to nearly one-third of PICU patients diagnosed with severe sepsis.
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Introduction
Sepsis is a leading cause of death in children worldwide,
responsible for an estimated 75,000 hospitalizations annu-
ally in the United States and nearly 50 % of all childhood
hospital deaths worldwide [1–5]. Within the spectrum of
this syndrome, severe sepsis refers to children with shock
or other organ dysfunction and is the high-risk group tar-
geted for interventional studies in the pediatric intensive
care unit (PICU) [6].
Investigators in clinical trials of severe sepsis face im-
portant challenges that have contributed to high failure
rates for many promising novel therapies, with few at-
tempts to include children [7]. One fundamental issue is
that the sepsis syndrome is characterized by non-specific
physiologic abnormalities that encompass a heteroge-
neous population. Consensus criteria for pediatric sepsis
were therefore established to facilitate consistent enroll-
ment across research studies [6]. Many of these criteria
have since been adopted for use in clinical practice [8];
however, published reports have demonstrated only mod-
erate overlap of physician diagnosis of severe sepsis with
consensus criteria [9, 10]. These findings raise concern
that many children diagnosed and treated for severe sepsis
in clinical practice may have important physiologic—and
outcome—differences from those studied in interventional
trials [9, 10].
The degree to which a study population is representa-
tive of patients diagnosed and treated in clinical practice
has a major impact on the external validity of a study
[11–13]. Although physician diagnosis serves clinical
practice and consensus criteria were intended primarily
for research, the alignment of these two methods to
identify children with severe sepsis will significantly im-
pact the extent to which study results translate into
effective care at the bedside. Moreover, criteria that pur-
posely define a disorder as a decompensated state at one
extreme of the entire spectrum—as the existing pediatric
consensus definitions currently do for severe sepsis and
septic shock—may hinder early clinical diagnosis or
delay enrollment in a clinical trial. Although the inher-
ent challenge between research efficacy and clinical
effectiveness is not limited to sepsis [14–17], under-
standing the extent to which consensus criteria for
pediatric severe sepsis are in agreement with clinical
practice will help to improve understanding of the utility
of these criteria and to identify ways to improve both
physician diagnosis and consensus definitions. To date,
the agreement of physician diagnosis with consensus cri-
teria for pediatric severe sepsis has not been evaluated in
a large-scale setting.
The Sepsis PRevalence, OUtcomes, and Therapies
(SPROUT) study researchers screened nearly 7000 PICU
patients for severe sepsis at 128 sites across 26 countries
using consensus criteria [18]. In addition, the attending
physician caring for each patient provided an independ-
ent diagnostic assessment for severe sepsis. Using these
data, we determined the level of agreement between
consensus criteria [6] and attending physician diagnostic
assessment (“physician diagnosis”) for pediatric severe
sepsis. We hypothesized that agreement would be mod-
erate at best, and thus we aimed to compare differences
in patient characteristics, treatment strategies, and out-
comes for children identified as having severe sepsis by
consensus criteria versus physician diagnosis.
Material and methods
Study design
SPROUT was a prospective point prevalence study per-
formed at 128 PICUs in 26 countries over the course of
5 study days spaced over 1 year [18]. Sites were recruited
by open invitation through established research net-
works, and participation was voluntary. Ethical approval
was obtained at all sites, and waiver of informed consent
was granted at all but three sites, at which written consent
was required for data collection (see Additional file 1 for a
list of all approving ethical bodies). The details of the
SPROUT study methodology have been published previ-
ously [18].
Study population
All patients <18 years of age being treated in a partici-
pating PICU at 9:00 AM local time on each study day
were screened for severe sepsis using a standardized
form incorporating the 2005 International Pediatric
Sepsis Consensus Conference criteria: (1) at least two
systemic inflammatory response syndrome criteria; (2)
confirmed or suspected invasive infection; and (3) car-
diovascular dysfunction, acute respiratory distress syn-
drome (ARDS), or at least two organ dysfunctions [6].
The subset of patients with septic shock defined by car-
diovascular dysfunction were included within the
spectrum of severe sepsis. Only data available within the
24 h preceding the 9:00 AM study day time were consid-
ered for screening, yielding a study cohort with active
severe sepsis. Patients who were ≥18 years of age, cor-
rected gestational age <42 weeks, or had surgery involv-
ing cardiopulmonary bypass in the preceding 5 days
were excluded.
To ascertain physician diagnosis of severe sepsis, an
investigator at each site provided a list of patients, using
a standardized form, to the attending physician of record
on each study day. Attending physicians were instructed
as follows: “In your clinical opinion, does this patient
(yes or no) meet criteria for severe sepsis and/or septic
shock when considering data only from the past 24 h
(i.e., 9:00 AM yesterday to 9:00 AM today)?” Attending
physicians who provided diagnoses were not involved
with screening of patients for severe sepsis by consensus
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criteria. Similarly, site investigators screening for consen-
sus criteria were blinded to physician diagnosis.
Data collection
Data were collected about demographics, comorbid condi-
tions, admission source, laboratory results, and therapies
within a 48-h window around the study day (9:00 AM be-
fore to 9:00 AM after the study day). Definitions for the
primary site of infection were adapted from published cri-
teria [18]. The day of severe sepsis recognition was identi-
fied as the first calendar day on which a patient met
consensus conference criteria for severe sepsis [6], and the
presence of new or progressive multiorgan dysfunction
syndrome (NPMODS) was measured for 7 days following
severe sepsis recognition [19–21]. New MODS was de-
fined as no or one organ dysfunction at sepsis recognition
with subsequent development of at least two organ dys-
functions. Progressive MODS was defined as existing mul-
tiorgan dysfunction syndrome (MODS) (at least two
organ dysfunctions) at sepsis recognition with develop-
ment of at least one other concurrent organ dysfunction.
For severe sepsis screening, organ dysfunctions were de-
fined using pediatric sepsis consensus conference criteria
[6], whereas more stringent criteria were used to define
NPMODS [21]. For severity of illness, the Pediatric Index
of Mortality (PIM)-3 score [22] was calculated at PICU
admission, whereas the Pediatric Logistic Organ Dysfunc-
tion (PELOD) score [23] was calculated on the study day.
Patients with severe sepsis were followed for 90 days
or until death or hospital discharge. Outcomes included
vasoactive- and ventilator-free days from day of severe
sepsis recognition through day 28, NPMODS, change in
functional status from admission to hospital discharge
(using the Pediatric Overall Performance Category [POPC]
1–6 ordinal scale [24]), and all-cause mortality at PICU
discharge. Patients surviving to hospital discharge were
classified as having “at least mild disability” for any in-
crease in POPC and “at least moderate disability” if dis-
charge POPC was 3 or higher and increased by at least 1
from baseline [25].
All data were recorded and managed using standard-
ized case report forms within the web-based Research
Electronic Data Capture (or REDCap) system, a secure
database that provides an intuitive interface for validated
data entry and audit trails for tracking data [26]. The
methods used to ensure data quality and confidentiality
have been published previously [18].
The primary outcome was the level of agreement in
identification of pediatric severe sepsis between phys-
ician diagnosis and consensus criteria. Secondary out-
comes included differences in patient characteristics,
therapies used, and clinical outcomes between patients
identified using physician diagnosis versus consensus
criteria.
Statistical analysis
Analyses were performed using STATA software (version
12.1; College Station, TX, USA). Data are presented as
medians with interquartile ranges for continuous vari-
ables and frequencies with percentages for categorical
variables. Comparisons between groups were performed
using the Kruskal-Wallis test for continuous variables,
and categorical variables were compared using Fisher’s
exact test. For variables in which significant differences
were identified across all three groups, pairwise compari-
sons were performed using Wilcoxon rank-sum or Fisher’s
exact tests for continuous or categorical variables, respect-
ively. The level of agreement between the two methods to
identify patients with severe sepsis was quantified using
percentage agreement and Cohen’s κ. Multivariable logis-
tic regression was used to test the independent association
of each definition of severe sepsis with PICU mortality
after controlling for patient-level variables found to be sig-
nificantly different across groups. Status as a developed
(North America, Australia/New Zealand, and Europe) or
resource-limited (Asia, Africa, and South America) region
did not provide significant effect modification when
tested as an interaction term with definition of severe
sepsis (p = 0.36), but it was included as a confounder
in the final logistic regression model. Statistical sig-
nificance was defined as a p value <0.05.
Results
Over the 5 study days, 6925 PICU patients were screened
across all sites. In total, 706 were identified with severe
sepsis by either consensus criteria or physician diagnosis,
with 137 patients (19.4 %) identified by physician diagno-
sis only, 301 (42.6 %) by both definitions, and 268 (38.0 %)
by consensus criteria only (Fig. 1). The percentage agree-
ment between consensus criteria and physician diagnosis
for identifying severe sepsis in the entire cohort of
screened patients was 94 %, but it was only 43 % for iden-
tifying severe sepsis among the 706 patients with sepsis by
either definition. The inter-rater agreement between phys-
ician diagnosis and consensus criteria achieved a moderate
κ ± standard error of 0.57 ± 0.02. The percentage agree-
ment between physician diagnosis and consensus criteria
varied significantly across geographic regions (p < 0.001).
Agreement was lowest in North America (31 % agreement
of 444 patients identified with severe sepsis by any cri-
teria); moderate in Australia and New Zealand (45 %) and
Europe (51 %); and highest in Asia (72 %), Africa (72 %),
and South America (85 %). The percentage agreement
was 44 %, 49 %, 45 %, 38 %, and 39 % across study days 1–
5, respectively, suggesting that clinicians did not alter their
diagnostic assessment to better comply with consensus
criteria over time.
Of the 438 total patients with a physician diagnosis of
severe sepsis, 31 % were not concurrently identified with
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severe sepsis by consensus criteria and thus would
have been ineligible to participate in a clinical trial
that enrolled patients based on the criteria established
by consensus guidelines. Moreover, 47 % of the pa-
tients identified as having severe sepsis by consensus
criteria—and thus potentially eligible for a clinical
trial—were not simultaneously considered to have se-
vere sepsis by physician diagnosis.
Characteristics of 704 of the patients identified with
severe sepsis by physician diagnosis alone, by both defi-
nitions, or by consensus criteria alone are shown in
Table 1. Data could not be obtained for two patients
(both identified by consensus criteria alone) who did not
consent to data collection at one site that required in-
formed consent for this purpose. Patients identified only
by physician diagnosis were younger (p = 0.008), had a
lower severity of illness (lower PIM-3 [p < 0.001] and
PELOD [p < 0.001] scores), and a lower proportion of
cardiovascular (p = 0.006) and hematologic dysfunction
(p < 0.001) at sepsis recognition than patients identified
by consensus criteria alone or both definitions. Patients
identified by consensus criteria alone were less likely to
be previously healthy (p = 0.002) and more likely to have
neuromuscular comorbidities (p < 0.001) than patients
identified by physician diagnosis alone or both defini-
tions. Patients identified by consensus criteria alone
were more likely to have respiratory (p = 0.004) or un-
known primary site of infection (p = 0.002) and less
likely to have primary bloodstream infection (p < 0.001).
Patients identified concurrently by both physician
diagnosis and consensus criteria had lower platelet
counts and higher blood lactate, C-reactive protein, and
procalcitonin levels than patients identified by either
criterion alone (all p < 0.01) (Table 2). Similarly, patients
identified by both physician diagnosis and consensus cri-
teria were also more likely to be treated with vasoactive
infusions, albumin, blood products, granulocyte/granulo-
cyte macrophage colony-stimulating factor, intravenous
immunoglobulin, and renal replacement therapy than
patients identified by either criterion alone (all p < 0.05)
(Table 3).
PICU mortality was significantly lower for patients
with only a physician diagnosis of severe sepsis (18 %)
than with both definitions (27 %; p = 0.02) and trended
lower than for consensus criteria alone (21 %; p = 0.29;
Table 4). The proportion with NPMODS, at least mild
disability, and at least moderate disability all trended
lower for patients identified with severe sepsis by phys-
ician diagnosis alone, but none reached statistical signifi-
cance. After controlling for age, PIM-3 score, number of
comorbid conditions, and treatment in developed versus
resource-limited regions, patients identified with severe
sepsis by physician diagnosis only or by consensus cri-
teria only did not have PICU mortality different from
that of patients identified by both physician diagnosis
and consensus criteria (Table 5).
Discussion
Across this large international network of PICUs, phys-
ician diagnosis and consensus criteria achieved only a
moderate level of agreement in identifying critically ill
children with severe sepsis. These findings suggest that
the results of a research study with enrollment based only
on current consensus criteria may not be generalizable to
nearly one-third of pediatric patients diagnosed with se-
vere sepsis in a PICU. Moreover, for nearly half of the pa-
tients identified with severe sepsis by consensus criteria,
and thus eligible for clinical trials, a diagnosis of severe
sepsis was not corroborated by the treating attending
physician.
The data in this study demonstrate that PICU physi-
cians worldwide commonly diagnose critically ill chil-
dren with severe sepsis who do not meet consensus
criteria. This finding is consistent with a prior report of
a single-center study in the United States [10]. In gen-
eral, patients with physician-diagnosed severe sepsis
tended to be younger, less severely ill, and less likely to
receive several sepsis-related therapies than patients who
also met consensus criteria. These observations likely re-
flect the intention of the International Pediatric Sepsis
Consensus Conference to identify a more severely ill
subgroup of critically ill children with severe sepsis for
enrollment in clinical trials [6]. It may therefore be ap-
propriate for physicians to diagnose severe sepsis more
often than consensus criteria, particularly in children
with a lower severity of illness who may need fewer ad-
junctive sepsis-related therapies. Physicians may also
Fig. 1 Venn diagram of the overlap between patients identified with
severe sepsis by attending physician diagnostic assessment (“physician
diagnosis”) and the 2005 International Pediatric Sepsis Consensus
Conference (“consensus criteria”). Of the 6925 pediatric intensive care
unit patients screened, 706 were identified with severe sepsis but only
301 (43 %) were concurrently identified by both physician diagnosis
and consensus criteria (κ 0.57 ± 0.02)
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Table 1 Characteristics of patients identified with severe sepsis by physician diagnosis, consensus criteria, or both
Characteristic Physician diagnosis Both criteria Consensus criteria p value*
N 137 301 266
Age (yr) 1 (0.5–7) 3 (0.7–10) 3 (0.7–11) 0.03
Sex, n (%) 0.74
Male 76 (55) 164 (55) 138 (52)
Female 61 (45) 137 (45) 128 (48)
Comorbid conditions, n (%)
Respiratory 54 (39) 73 (24) 99 (37) 0.001
Gastrointestinal 40 (29) 62 (21) 79 (30) 0.03
Cardiovascular 34 (25) 62 (21) 74 (28) 0.13
Genetic 35 (26) 54 (18) 61 (23) 0.14
Hematologic/immunologic 28 (20) 69 (23) 45 (17) 0.21
Neuromuscular 11 (8) 37 (12) 60 (23) <0.001
Neoplastic 18 (13) 51 (17) 29 (11) 0.11
Prematurity 37 (12) 24 (18) 39 (15) 0.35
Metabolic 17 (12) 28 (9) 34 (13) 0.38
Renal 15 (11) 24 (8) 31 (12) 0.31
Solid organ/stem cell transplant 8 (6) 28 (9) 26 (10) 0.39
Comorbid conditions, n (%) <0.001
None 30 (22) 85 (28) 43 (16)
1 21 (15) 77 (26) 64 (24)
≥ 2 86 (63) 21 (15) 159 (60)
Admission POPC, n (%) 0.13
Good performance 70 (51) 170 (56) 120 (45)
Mild disability 26 (19) 44 (15) 41 (15)
Moderate disability 22 (16) 44 (15) 46 (17)
Severe disability or coma 19 (14) 43 (14) 59 (22)
PIM-3 scorea 3.6 (1.4–5.5) 4.4 (1.9–9.2) 4.3 (1.8–9.9) <0.001
PELOD scoreb 10 (1–11) 11 (2–13) 11 (2–12) <0.001
Source of admission, n (%) 0.86
Emergency departmentc 41 (30) 89 (30) 78 (29)
Hospital floor 39 (29) 92 (31) 66 (25)
Operating room 12 (9) 28 (9) 22 (8)
Other hospitald 39 (28) 77 (26) 89 (33)
Organ dysfunction at sepsis recognitione
Cardiovascular 51 (37) 182 (61) 106 (40) <0.001
Respiratory 88 (64) 211 (70) 197 (74) 0.12
Renal 5 (4) 19 (6) 7 (3) 0.10
Hepatic 2 (1) 16 (5) 6 (2) 0.07
Hematologic 4 (3) 49 (16) 24 (9) <0.001
Neurologic 9 (7) 28 (9) 33 (12) 0.17
Primary site of infection, n (%)
Respiratory 60 (44) 101 (34) 127 (48) 0.002
Primary bloodstream 25 (18) 82 (27) 26 (10) <0.001
Abdominal 15 (11) 31 (10) 16 (6) 0.11
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have been recognizing and treating children with sepsis
earlier in their illness course, at a point when they may
not yet have manifested the physiologic and laboratory
derangements required by consensus criteria. The loss of
a statistical difference in PICU mortality between pa-
tients identified by physician diagnosis alone and those
identified by both definitions after correcting for severity
of illness is consistent with these suppositions. A lower
threshold for diagnosing severe sepsis in clinical practice
likely accounts for the generally better outcome metrics
identified in epidemiologic studies using administrative
databases [1, 2, 5] than has been reported in clinical trials
[20, 27-29]. Our study therefore suggests caution when
extrapolating results from epidemiologic, observational,
Table 2 Laboratory values within the 48-h data collection window by definition of severe sepsis
Laboratory examination Physician diagnosis Both criteria Consensus criteria p value*
Percenta Median (IQR) Percenta Median (IQR) Percenta Median (IQR)
WBC, max (103/μl) 92 % 10.1 (7.3–16.6) 97 % 14.9 (7.5–22.7) 91 % 14.6 (8.8–20.8) <0.001
Platelets, min (103/μl) 91 % 148 (70–262) 96 % 95 (39–195) 89 % 157 (77–287) <0.001
BUN, max (mg/dl) 83 % 13 (8–22) 93 % 21 (12–41) 92 % 18 (10–31) <0.001
Creatinine, max (mg/dl) 92 % 0.4 (0.3–0.6) 97 % 0.5 (0.3–0.9) 97 % 0.4 (0.3–0.7) <0.001
ALT, max (IU/L) 55 % 39 (25–67) 77 % 53 (28–123) 62 % 50 (26–110) 0.09
Total bilirubin, max (mg/dl) 53 % 0.7 (0.4–1.7) 73 % 1.0 (0.5–2.9) 59 % 0.7 (0.4–3.0) 0.02
Albumin, min (g/dl) 66 % 2.6 (2.2–3.0) 81 % 2.5 (2.2–3.0) 71 % 2.8 (2.3–3.3) <0.001
INR, max 37 % 1.3 (1.2–1.7) 64 % 1.3 (1.2–1.8) 42 % 1.3 (1.1–1.8) 0.80
Lactate, max (mmol/L) 62 % 1.4 (1.1–2.0) 75 % 2.0 (1.2–3.8) 62 % 1.6 (1.1–2.8) 0.001
ScvO2, min (%) 28 % 70 (57–75) 46 % 65 (52–74) 30 % 65 (49–73) 0.50
PaO2/FiO2 ratio, min (mmHg) 47 % 138 (89–233) 72 % 160 (100–236) 51 % 144 (87–275) 0.79
C-reactive peptide, max (mg/dl) 39 % 7.1 (2.1–17.8) 64 % 9.3 (2.8–20.8) 43 % 3.8 (1.6–9.7) <0.001
Procalcitonin, max (ng/ml) 12 % 3.5 (1.1–11.6) 22 % 6.4 (1.4–23.0) 6 % 1.3 (0.24–5.4) 0.01
max maximum value within the 48-h window around the study day (9:00 AM before to 9:00 AM after the study day), min minimum value within the 48-h window
around the study day (9:00 AM before to 9:00 AM after the study day), PaO2/FiO2 ratio of partial pressure of oxygen to fraction of inspired oxygen, WBC white
blood cell count, BUN blood urea nitrogen, ALT alanine aminotransferase, INR international normalized ratio, ScvO2 central venous oxygen saturation
*Statistical comparisons using Kruskal-Wallis test
aProportion of each group with available laboratory results
Table 1 Characteristics of patients identified with severe sepsis by physician diagnosis, consensus criteria, or both (Continued)
Central nervous system 3 (2) 9 (3) 16 (6) 0.11
Genitourinary 7 (5) 12 (4) 9 (3) 0.67
Skin 4 (3) 16 (5) 4 (2) 0.04
Other 6 (4) 16 (5) 13 (5) 0.95
Unknown 17 (12) 34 (11) 55 (21) 0.006
Microbiology,f,g n (%)
Gram-positive bacteria 39 (28) 90 (30) 60 (23) 0.13
Gram-negative bacteria 27 (20) 95 (32) 63 (24) 0.02
Fungus 9 (7) 39 (13) 37 (14) 0.07
Virus 35 (26) 50 (17) 69 (26) 0.01
No organism identified 50 (36) 95 (32) 101 (38) 0.25
Data are presented as median (IQR) unless otherwise noted
POPC Pediatric Overall Performance Category, ScvO2 central venous oxygen saturation, PIM-3 Pediatric Index of Mortality-3, PELOD Pediatric Logistic Organ Dysfunction,
PICU pediatric intensive care unit
*Statistical comparisons using Kruskal-Wallis or Fisher’s exact test
aPIM-3 measured at time of PICU admission
bPELOD score calculated from data within a 48-h time window around the study day (9:00 AM before to 9:00 AM after the study day)
cEmergency department at the same hospital as the PICU
dOther hospital includes emergency department at another hospital
eBased on organ dysfunction criteria defined by the International Pediatric Sepsis Consensus Conference [6]
fCategories do not add up to 100 %, as some infections were polymicrobial
gSources of positive isolates included blood, urine, cerebrospinal fluid, respiratory (nasopharynx, tracheal, bronchoalveolar lavage), stool, wound, and other
normally sterile body fluids (pleural, pericardial, peritoneal)
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and interventional studies to this less severely ill subgroup
of patients who are diagnosed on the basis of physician
impression and do not meet consensus criteria. Con-
versely, the absence of certain features, such as two or
more systemic inflammatory response syndrome criteria
[30, 31], hypotension only after 40 ml/kg of intravenous
fluid, and laboratory derangements beyond arbitrary cut-
points (e.g., international normalized ratio >2), should not
preclude the clinical diagnosis of severe sepsis and/or sep-
tic shock. A refined consensus definition that more closely
matches the clinical definition and establishes a spectrum
of risk concordant with outcome, similar to that of the re-
cent at-risk, mild, moderate, and severe pediatric ARDS
definitions [32], would benefit both research scientists and
clinicians.
By quantifying the extent to which physician diagnosis
and consensus criteria overlap, one can better under-
stand the potential loss of efficacy as research findings
are adopted at the bedside. Previous studies show that
efficacious therapies in clinical trials are often extended
to a broader patient population, with a more variable
and perhaps even a distinct pathophysiology [14–17]. To
our knowledge, this is the first multicenter, international
study of the generalizability of consensus criteria for
pediatric severe sepsis. Because only 69 % of patients
with a physician’s diagnosis of severe sepsis met consen-
sus criteria, it may not be appropriate to apply the re-
sults of a clinical trial to up to one-third of children
treated for severe sepsis in a general PICU practice. Al-
though a potential decrement from efficacy to effectiveness
may not dissuade widespread implementation of a new
therapy, enthusiasm could be altered if concerns over ad-
verse effects, resource utilization, or costs were taken into
consideration.
It is also noteworthy that nearly half of patients in the
SPROUT study were identified as having severe sepsis by
consensus criteria without corroboration by physician
diagnosis. This likely reflects that both physician diagno-
sis and consensus criteria rely on relatively non-specific
Table 3 Therapies used within the 48-h data collection window
by definition of severe sepsis
Therapy Physician
diagnosis
Both
criteria
Consensus
criteria
p value*
Vasoactive infusionsa 53 (39) 209 (69) 105 (39) <0.001
Invasive mechanical
ventilation
92 (67) 229 (76) 192 (72) 0.14
Corticosteroids 46 (36) 132 (44) 110 (41) 0.13
Albumin 24 (18) 90 (30) 45 (17) <0.001
Blood productsb 39 (28) 159 (53) 73 (27) <0.001
Insulinc 4 (3) 32 (11) 25 (9) 0.02
G/GM-CSF 2 (1) 17 (6) 6 (2) 0.04
IVIG 7 (5) 28 (9) 10 (4) 0.02
RRTd 13 (9) 57 (19) 24 (9) 0.001
Plasma exchange 1 (1) 3 (1) 2 (1) 0.94
ECMO 3 (2) 14 (5) 16 (6) 0.23
Data presented as n (%)
G/GM-CSF granulocyte/granulocyte-monocyte colony stimulating factor,
IVIG intravenous immunoglobulin, RRT renal replacement therapy,
ECMO extracorporeal membrane oxygenation
*Statistical comparisons using Fisher’s exact test
aIncludes dopamine >5 μg/kg/min, dobutamine >5 μg/kg/min, or any dose of
epinephrine, norepinephrine, vasopressin, phenylephrine, milrinone,
levosimendan, or vasodilator
bIncludes packed red blood cells, platelets, fresh frozen plasma,
cryoprecipitate, granulocytes, and whole blood
cIncludes intravenous insulin by continuous infusion only
dIncludes hemodialysis, all continuous renal replacement modalities, and
peritoneal dialysis
Table 4 Clinical outcomes by definition of severe sepsis
Outcome Physician
diagnosis
Both
criteria
Consensus
criteria
p value*
Vasoactive-free days,
median (IQR)
27 (22–28) 22 (6–26) 26 (17–28) <0.001
Ventilator-free days,
median (IQR)
19 (2–27) 16 (0–24) 18 (0–26) 0.07
NPMODSa 47 (34) 131 (44) 97 (36) 0.10
PICU mortality 23 (17) 82 (27) 57 (21) 0.042
At least mild disabilityb 24 (22) 67 (31) 50 (24) 0.15
At least moderate
disabilityc
14 (13) 36 (17) 37 (18) 0.46
Data presented as n (%) unless otherwise noted
IQR interquartile range, NPMODS new or progressive multiorgan dysfunction
syndrome, PICU pediatric intensive care unit
*Statistical comparisons using Kruskal-Wallis or Fisher’s exact test
aNPMODS considered starting the day after sepsis recognition
bAny increase in Pediatric Overall Performance Category from baseline to
hospital discharge in the 534 hospital survivors
cDischarge Pediatric Overall Performance Category ≥3 and an increase of at
least 1 from baseline in the 534 hospital survivors
Table 5 Multivariable logistic regression model of the association
of severe sepsis definition with PICU mortality
Variable Adjusted ORa 95 % confidence
interval
p value
Severe sepsis definition
Both criteria Reference
Physician diagnosis, only 0.64 0.37–1.11 0.12
Consensus criteria, only 0.73 0.48–1.12 0.15
Age, yr 0.99 0.95–1.02 0.45
PIM-3 score 1.04 1.03–1.06 <0.001
Comorbid conditions
None Reference
1 comorbid condition 1.11 0.62–2.01 0.72
≥2 comorbid conditions 1.78 1.07–2.99 0.03
Developed regionb 0.63 0.37–1.06 0.08
OR odds ratio, PIM-3 Pediatric Index of Mortality-3
aOdds ratios are adjusted for all of the variables listed
bSites included as “developed regions” were located in North America,
Australia/New Zealand, and Europe
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changes in physiology that are commonly found in crit-
ically ill children in general, not just in children with
sepsis. Still, this observation highlights an opportunity to
refine future iterations of consensus criteria and address
variability in physician diagnosis to identify sepsis. Pa-
tients with preexisting neuromuscular disorders, such as
cerebral palsy and epilepsy, were particularly likely to
meet consensus criteria for severe sepsis despite an alter-
native clinical diagnosis. Many of these patients have
dysautonomia or altered physiologic responses to illness
that make it challenging to apply predefined rigid cri-
teria. The higher rate of unknown primary site of infec-
tion suggests that consensus criteria may be less specific
than physician diagnosis in identifying patients with a
true infection. It is also possible that consensus criteria
include PICU patients with a high severity of illness,
namely those with shock and multiorgan system dys-
function caused by non-septic insults, who are com-
monly treated empirically for infection even if clinical
suspicion is low. Alternatively, if physician diagnosis
does not corroborate consensus criteria despite true
presence of severe sepsis, there may be a higher rate of
parental or clinician refusal to participate in research
because the clinicians managing the patient may not
agree on the diagnosis of concern. The incorporation
of new biomarkers or novel microbiologic detection
systems that improve early sensitivity and specificity
for invasive infections into future revisions of the con-
sensus criteria may improve alignment with physician
diagnosis.
There are several limitations to this study. First, phys-
ician diagnosis and the application of consensus criteria
to identify patients with severe sepsis could not be inde-
pendently verified. The reasons why patients were not
identified as having severe sepsis by one or both defini-
tions were also not available. Although these concerns
may have led to misclassification of some patients, it is
unlikely that such a bias would have preferentially af-
fected one group. Moreover, because we included only
physicians practicing in a PICU setting, 89 % of whom
were trained in pediatric critical care medicine, the level
of agreement for other providers who commonly treat
sepsis (e.g., emergency physicians) may differ from our
results. A second limitation is that criteria used for phys-
ician diagnosis were not standardized. Although this
may have increased variability in physician diagnosis
across providers and sites, such an approach reflects that
physicians often differ in their diagnostic approach.
Third, the higher proportion of patients with available
laboratory measures in the consensus criteria only and
both definition groups may itself have increased the like-
lihood of identification by consensus criteria because, in
the absence of available data, these measures were as-
sumed to be within normal limits. Although it is more
likely that sicker patients had directed laboratory testing
performed than unsuspected organ dysfunction was dis-
covered through routine laboratory testing, differential
availability of laboratory results may have been a source
of misclassification bias. Finally, because a “gold stand-
ard” does not exist, it is not possible to determine the
degree to which either definition correctly identified
pediatric patients with severe sepsis or compared the
sensitivity and specificity of the two definitions.
Conclusions
Physician diagnosis of pediatric severe sepsis achieved
only a moderate level of agreement with consensus cri-
teria across this multicenter, international point preva-
lence study. The results of a research study based on
current consensus criteria may not be generalizable to
nearly one-third of pediatric patients diagnosed with se-
vere sepsis in a PICU. Further research is needed to
understand the extent to which the specificity of consen-
sus criteria and variability in physician diagnosis may be
contributing to this discordant identification of pediatric
severe sepsis. Attempts to better align consensus defini-
tions with clinical diagnosis by establishing a continuous
spectrum of illness severity are needed.
Key messages
 Although consensus criteria for pediatric sepsis were
established to facilitate consistent enrollment across
research studies, the extent to which these criteria
reflect physician diagnosis of severe sepsis, which
underlies external validity for pediatric sepsis
research, is not known.
 Of 6925 PICU patients screened at 128 PICUs in 26
countries, 706 patients were identified by physician
diagnosis and/or consensus criteria as having severe
sepsis.
 Only 301 patients (42.6 %) were identified by both
physician diagnosis and consensus criteria
(κ 0.57 ± 0.02).
 The 31 % of patients with physician-diagnosed
severe sepsis who did not meet consensus criteria
were younger, had a lower severity of illness, and a
lower PICU mortality than those who met
consensus criteria or both definitions.
 The results of a research study based on consensus
criteria may have limited generalizability to nearly
one-third of PICU patients diagnosed with severe
sepsis.
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